Literature DB >> 30690600

Selected Clinical Features of Coccidioidomycosis in Dogs.

Autumn P Davidson1, Lisa F Shubitz2, Cody J Alcott3, Jane E Sykes1.   

Abstract

Canine coccidioidomycosis, a systemic fungal infection endemic to arid and semiarid regions of North, Central, and South America, is commonly diagnosed in dogs living in or traveling through lower Sonoran life zones in the states of California and Arizona. Canine and human cases have geographic overlap. Similarities between clinical coccidioidomycosis in dogs and humans include asymptomatic infection, primary respiratory disease and disseminated disease. Differences include a high rate of dissemination in dogs, differences in predilection of dissemination sites, and a granulomatous or diffuse meningoencephalopathic form in the canine central nervous system (CNS) without the obstructive component seen in humans. Dogs presenting with CNS coccidioidomycosis most commonly experience seizures. Prior disease history and serology are unreliable indicators of CNS coccidioidomycosis. Magnetic resonance imaging (MRI) is advantageous for diagnosis of CNS coccidioidomycosis in dogs. Long-term administration of antifungal medication is promoted for treatment of both primary and disseminated coccidioidomycosis in dogs. Supportive treatment addressing pain, fever, inappetance, coughing, and other clinical signs improves patient care. Glucocorticoids and or anticonvulsants are also recommended for canine disseminated CNS disease. Protracted treatment times, lack of owner compliance, failure of the disease to respond to the first antifungal drug selected, and high cost are challenges of successfully treating dogs.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30690600     DOI: 10.1093/mmy/myy113

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  5 in total

1.  Use of Fluconazole-impregnated Beads to Treat Osteomyelitis Caused by Coccidioides in a Pigtailed Macaque (Macaca nemestrina).

Authors:  Charlotte E Hotchkiss; Dean A Jeffery; Keith W Vogel
Journal:  Comp Med       Date:  2022-07-14       Impact factor: 1.565

2.  A promising candidate vaccine for coccidioidomycosis.

Authors:  F Javier Cabañes
Journal:  Rev Iberoam Micol       Date:  2022-06-29       Impact factor: 1.385

3.  Clinical performance of a point-of-care Coccidioides antibody test in dogs.

Authors:  Krystle L Reagan; Ian McHardy; George R Thompson; Jane E Sykes
Journal:  J Vet Intern Med       Date:  2021-03-06       Impact factor: 3.333

4.  Case Report: Successful Management of a Compressive Intraspinal Coccidioides Species Granuloma in a Cat.

Authors:  Hannah Dowdy; Jason E Evans; Jared A Jaffey; Kathryn L Wycislo; Jason D Struthers; Eric T Hostnik
Journal:  Front Vet Sci       Date:  2022-01-03

5.  Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis.

Authors:  Lisa F Shubitz; Edward J Robb; Daniel A Powell; Richard A Bowen; Angela Bosco-Lauth; Airn Hartwig; Stephanie M Porter; Hien Trinh; Hilary Moale; Helle Bielefeldt-Ohmann; James Hoskinson; Marc J Orbach; Jeffrey A Frelinger; John N Galgiani
Journal:  Vaccine       Date:  2021-10-23       Impact factor: 4.169

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.